Highest-materiality recent filing
Biogen completes $5.3B acquisition of Apellis; stockholders get $41 cash + CVR up to $4
Tender offer accepted 105.7M shares (~82.4%); merger effective May 14, 2026.
Compensation committee approved amendment to Executive Separation Benefits Plan on April 28, 2026, in connection with Biogen merger.
Biogen to acquire Apellis for $41/share plus CVRs up to $4, total up to $45/share
Biogen to pay $41.00 per share cash upfront plus one CVR per share for Apellis (APLS).
Apellis adds Dr. Mikael Dolsten as independent Class I director
Dr. Mikael Dolsten elected to Apellis Board as Class I director effective March 1, 2026, serving until the 2027 annual meeting.
Full-year 2025 preliminary U.S. net product revenues: SYFOVRE $587M, EMPAVELI $102M, total $689M.
Apellis enters $275M royalty buy-down with Sobi; reduces Aspaveli royalties 90%
Sobi pays Apellis $275M upfront; up to $25M more on EMA approval of Aspaveli for C3G and IC-MPGN.
Elected A. Sinclair Dunlop (54.1M for, 26.0M withheld), Alec Machiels (62.3M for, 17.8M withheld), Keli Walbert (76.95M for, 3.18M withheld) as Class II directors for three-year terms.
Apellis appoints Craig A. Wheeler to Board, effective April 17, 2025
Craig A. Wheeler elected as Class III director; will serve until 2026 annual meeting.
Apellis reports $709M preliminary FY2024 U.S. net product revenue, COO Townsend to depart
Preliminary FY2024 U.S. net product revenues $709M; SYFOVRE $611M (120% YoY growth), EMPAVELI $98M.
Apellis/Sobi Phase 3 VALIANT meets primary endpoint; 68% proteinuria reduction in C3G/IC-MPGN
Statistically significant 68% proteinuria reduction vs placebo (p<0.0001) at Week 26.
Apellis stockholders elect directors, ratify auditor, approve executive pay at 2024 annual meeting
Paul Fonteyne elected with 98,837,712 votes for and 5,320,270 withheld; Stephanie Monaghan O'Brien elected with 80,481,023 for and 23,672,152 withheld.
Apellis closes $375M senior secured term loan; buys out SFJ Pharmaceuticals liability
Apellis entered $475M credit facility with Sixth Street; initial draw $375M; maturity May 2030 at SOFR+5.75% (1% floor).
Apellis FY2023 revenue $396.6M, SYFOVRE drives 160k+ doses; net loss $528.6M
Full year 2023 total revenue $396.6M (vs $75.4M in 2022); SYFOVRE $275.2M, EMPAVELI $91.0M.
Apellis appoints Adam Townsend as Chief Operating Officer, effective immediately
Adam Townsend, 47, previously Chief Commercial Officer since Nov 2018, assumes additional COO role.
Apellis reports preliminary Q4 2023 U.S. net product revenue of $138M, full year $366M
Q4 2023 U.S. net product revenue ~$138M: SYFOVRE $114M, EMPAVELI $24M.
CHMP negative trend vote on MAA for intravitreal pegcetacoplan for geographic atrophy (GA) after Dec 13 oral explanation.
Apellis updates SYFOVRE label to include rare retinal vasculitis risk; rate 0.01% per injection
Updated USPI Warnings/Precautions and Postmarketing Experience sections to include retinal vasculitis with/without occlusion.
Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated
Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.
Apellis reports preliminary SYFOVRE Q3 revenue ~$74M; total since launch ~$160M
Approximately $74M in preliminary US net SYFOVRE revenue for Q3 2023; ~$160M total since March 2023 launch.
Apellis announces 25% workforce reduction, expects up to $300M cost savings through 2024
Reduce workforce by ~225 employees (~25% of total); substantially complete in Q3 2023.
Over 100,000 SYFOVRE vials distributed; 8 confirmed retinal vasculitis events (5 occlusive, 3 non-occlusive) as of June 20.
Apellis Q2 revenue $95.0M; SYFOVRE sales $67.3M; net loss $122.0M
Total US net product revenue of $89.6M: SYFOVRE $67.3M (GA), EMPAVELI $22.3M (PNH).
Apellis reports 6 retinal vasculitis events after SYFOVRE; rate ~0.01% per injection
Six retinal vasculitis events observed after first SYFOVRE injection, 7-13 days post-dose; no specific lot implicated.
Apellis stockholders re-elect Gerald Chan and Cedric Francois as Class III directors
Gerald Chan received 82,568,712 votes for and 19,616,976 withheld (5,095,730 broker non-votes).
FDA extends PDUFA goal date for Apellis' EMPAVELI Injector sNDA
FDA notified Apellis on March 14, 2023 that labeling review is ongoing and the March 15, 2023 PDUFA goal date will be missed.
Apellis prices $350M public offering of common stock and pre-funded warrants
Offering of 3,174,603 shares at $63.00/share and pre-funded warrants for 2,380,956 shares at $62.9999/warrant.
Apellis reports preliminary 2022 EMPAVELI US net sales of ~$65M; NDA and MAA submitted
Preliminary unaudited 2022 US net product revenue for EMPAVELI ~$65 million.
Apellis CMO Federico Grossi departs; Caroline Baumal named new CMO effective Jan 3, 2023
Federico Grossi, M.D., Ph.D., leaves as Chief Medical Officer effective Jan 3, 2023 to pursue new career opportunities.
Apellis reports 24-month Phase 3 data: pegcetacoplan shows increasing efficacy in GA
At 24 months, monthly pegcetacoplan reduced GA lesion growth 19% in DERBY (p=0.0004) and 22% in OAKS (p<0.0001) vs sham.
Apellis exchanges $22.5M convertible notes for shares; prior $75.6M exchange closed Aug 1
Signed exchange agreements on July 28 to convert $22.5M in 3.5% convertible notes due 2026 into common stock.
Apellis exchanges $75.6M of convertible notes for common stock shares
Exchanged ~$65.9M principal for 2,036,886 shares; ~$9.7M for 195,809 shares plus additional based on VWAP.
FDA accepted and granted Priority Review for intravitreal pegcetacoplan NDA for geographic atrophy (GA).
A. Sinclair Dunlop re-elected with 67,011,560 for vs 19,188,626 against, 8,818,334 broker non-votes.
Apellis prices public offering of 7.4M shares at $47/sh, raising $350M gross
7,446,809 shares at $47.00 per share; gross proceeds of $350 million.
Apellis reports positive 18-month Phase 3 data for pegcetacoplan in GA; NDA planned Q2 2022
OAKS GA: monthly pegcetacoplan reduced lesion growth 22% (p<0.0001); every-other-month 16% (p=0.0018) at month 18.
Apellis enters $300M at-the-market equity offering with Jefferies LLC
Apellis may sell up to $300M common stock in at-the-market offerings through Jefferies LLC.
Apellis reports preliminary EMPAVELI FY2021 U.S. net product revenue of ~$15M
Preliminary FY2021 U.S. net product revenue for EMPAVELI ~$15 million (unaudited).
Apellis Pharmaceuticals prices $350M public offering of 8.75M shares at $40/share
Apellis priced public offering of 8.75M shares at $40.00/share for gross proceeds of $350M.
Apellis announces mixed Phase 3 GA trial results; OAKS met primary endpoint, DERBY missed
OAKS trial met primary endpoint: monthly pegcetacoplan reduced GA lesion growth by 22% (p=0.0003), every-other-month by 16% (p=0.0052) vs sham at 12 months.
Apellis appoints Jim Chopas as VP, Corporate Controller and CAO
Jim Chopas named VP, Corporate Controller and principal accounting officer, effective August 30, 2021.
Apellis principal accounting officer Nicole Perry to depart Aug 30, 2021
Nicole Perry will transition from principal accounting officer role effective August 30, 2021.
Apellis closes exchange of $201.1M convertible notes for 5.99M common shares
Exchanged $201.1M principal of 3.500% Convertible Senior Notes due 2026 for 5,992,217 common shares.
Apellis exchanges $198.6M in convertible notes for common stock; closing July 23
Agreed to exchange ~$198.6M principal of 3.500% Convertible Senior Notes due 2026 for shares.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
the director of Purchaser as of immediately prior to the Effective Time, Michael Dambach, became the director of the Company.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
On April 17, 2025, the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), elected Craig A. Wheeler to the Board as a Class III director to serve until the Annual Meeting of Stockholders to be held in 2026 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
On January 10, 2025, the Company and Adam Townsend mutually agreed that Mr. Townsend will resign as the Company’s Chief Operating Officer effective as of February 21, 2025 (the “Separation Date”).
Max materiality 1.00 · Median 0.70 · Most common event other_material